(866) 389-4659
Regenerative Therapeutics

Advancing cell therapy from bench to bedside

FDA-licensed cord blood-derived cell therapies. An active clinical pipeline. 27 years of stem cell science translated into patient outcomes.

FDA
FDA Biologics License
US License 2280 · Approved 2024
2,300+ transplants
Across 325+ institutions
Biologics Programs
Cord blood-derived · Research & manufacturing
GMP
FDA-licensed facility
Available
HPC, Cord Blood · Phase IIa · NCT05682560
85%
fatigue resolution vs 20% placebo
Completed · Published
HPC, Cord Blood · Phase II
Phase II
Approved
Active
FDA US License 2280 RMAT Designation FACT Accredited AABB Accredited 325+ Institutions

Medical information inquiries

Product information, clinical data requests, and medical affairs inquiries.

Contact Medical Affairs